Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

Core Insights - Nuwellis, Inc. has expanded its pediatric footprint to 47 centers nationwide, including six of the top 10 children's hospitals, highlighting the strategic importance of this category [2][3] Pediatric Growth - The pediatric category now accounts for approximately 50% of total U.S. revenue, marking a significant milestone for the company [2] - Strong utilization is observed within established programs, with growing interest from additional centers for precision fluid management solutions for complex pediatric patients [2][4] Aquadex Therapy Platform - The Aquadex therapy platform is FDA-cleared for use in pediatric and adult patients weighing 20 kg and above, designed for precise ultrafiltration to manage fluid overload in critically ill children [3] - Continued pediatric expansion is viewed as a strategic growth catalyst, supported by high-acuity use cases and institutional adoption [3][4] Institutional Adoption - Adoption within leading pediatric centers reflects the increasing recognition of the need for precision fluid management in vulnerable populations [4] - The company aims to support clinical evidence development and expand market access as part of its strategy [4] Company Overview - Nuwellis, Inc. focuses on advancing precision fluid management technologies across the cardiorenal continuum, developing solutions for both acute and chronic care settings [5] - The company's portfolio includes technologies addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [5] Aquadex SmartFlow System - The Aquadex SmartFlow system is indicated for temporary or extended use in patients weighing 20 kg or more, specifically for those whose fluid overload is unresponsive to medical management [6] - Treatments must be administered by trained healthcare providers in clinical settings under physician prescription [6]